An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Phase 1CompletedNCT00207116

Eli Lilly and Company120 enrolled

Overview

The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

120

Conditions

Carcinoma, Non-Small-Cell Lung Neoplasm Metastasis

Interventions

CetuximabDRUG

IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Measurable disease tumor available for biopsies * Life expectancy of at least 3 months Exclusion Criteria: * Known or documented brain metastases prior to Cetuximab therapy

Locations (1)

Local Institution

Newark, Delaware, United States

Outcomes

Primary Outcomes

Prediction of response to Erbitux with non small cell lung cancer

Secondary Outcomes

Radiographic Response

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.